XNAS · Biotechnology
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$19.85-2.36%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
21/100
Weak
Score components
TickerWhale View
Denali Therapeutics scores 21 out of 100 overall, which we rate weak. Risk is its strongest area and Quality & growth its weakest.
What helps
- Risk
- Sentiment Signal
What to watch
- Technical
- Quality & growth
- Valuation
Quality & growth
30%1Weak
- Revenue growth n/a
- EPS growth n/a
Valuation
25%2Weak
- P/E -7.3
- EV/Sales 978.4
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#138 / 139sector rank by TickerWhale Score
TickerWhale Score 21 vs sector average 54.6 (-33.6)
Return on equity (industry)Top 70%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
31/100Weak vs universe
Ranks 31st of 100 covered names on our technical composite — the composite itself scores 42/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 2 sell · 3 neutral of 8 votes
TickerWhale rates DNLI's technical setup weak — 31st percentile of the covered universe. Classic chart indicators lean buy — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
4 / 9constructive
- vs 200-day-6.6%
- vs 50-day-0.8%
Momentum
Mixed
- RSI (14)52 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Constructive
- ADX (14) trend strength21· trending
- MACD (12,26,9)buy(histogram 0.238)
How the classic verdict is reached
Moving averages (9) agree on sell — 4 buy vs 5 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 1 sell · 3 neutral.
Result — 3 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)-7.3 · TTM loss
- P/S (TTM)1032.8
- P/B4.5
- EV/EBITDA—
- EV/Sales978.4
- PEG—
Profitability & returns
- Gross margin—
- Net margin-14244.7%
- ROE-58.2%
- Debt/Equity0.01
Growth
- Revenue growth (YoY)—
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $3.7B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DNLICurrentDenali Therapeutics | 21 | 42 | -7.3 | — | 4.5 | 978.4 | $19.85 | -2.36% | — | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.